Lantern Pharma Engages IBN to Enhance Corporate Communications as It Advances AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN), a biotechnology firm at the forefront of using artificial intelligence (AI) to revolutionize oncology drug development, has announced a strategic partnership with InvestorBrandNetwork (IBN) to spearhead its corporate communications efforts. This collaboration comes at a pivotal time as Lantern Pharma advances its innovative pipeline of precision oncology therapies, powered by its proprietary RADR(R) AI platform. The company's clinical programs are currently targeting a range of cancers, including lung, brain, breast, and blood cancers, with three AI-guided candidates and a subsidiary focused on central nervous system (CNS) therapies already in active trials.

The engagement with IBN is designed to amplify investor awareness and communication as Lantern Pharma approaches significant milestones in its data-driven, biomarker-informed pipeline. The RADR(R) platform, which integrates over 200 billion oncology-focused data points and utilizes more than 200 machine learning algorithms, has enabled Lantern Pharma to significantly reduce the time and cost associated with bringing new oncology therapies from the lab to clinical trials. On average, the company's drug programs have progressed from initial AI insights to first-in-human clinical trials in just 2-3 years, with an approximate cost of $2.5 million per program.

This partnership underscores the growing importance of AI in the biotech sector and highlights Lantern Pharma's commitment to leveraging cutting-edge technology to address unmet needs in cancer treatment. By enhancing its corporate communications strategy through IBN's extensive network and expertise, Lantern Pharma aims to better articulate its vision and progress to investors and the broader medical community. The collaboration is expected to play a crucial role in the company's efforts to secure additional funding and partnerships, further accelerating the development of its promising oncology therapies.

For more details on Lantern Pharma's innovative approach to oncology drug development and its partnership with IBN, visit https://ibn.fm/6gYcX. Additional information and updates regarding Lantern Pharma can be found in the company's newsroom at https://ibn.fm/LTRN.